ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2025
The effect of alpha-lipoic acid supplementation on vascular function and inflammation in patients newly experienced stroke.
Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Since inflammation and oxidative stress are risk factors for cardiovascular diseases, so it seems that α-lipoic acid consumption as a potent antioxidant can improve vascular function and reduce the risk of vascular disease. The aim of this study is determine the impact of ALA supplementation on vascular function and inflammatory markers in patients who newly experienced stroke. Materials and Methods: In this randomized double-blind, placebo-controlled clinical trial, 80 patients were randomly divided into two groups: α-lipoic acid (600 mg ALA daily for 12 weeks) and placebo groups. Serum concentration of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) were measured by the ELISA method, and carotid intima-media thickness (CIMT) and flow-mediated dilation (FMD) were assessed using the Doppler ultrasound method. All statistical analyses were conducted using SPSS-16 and Results: After 12 weeks' supplementation, CIMT, FMD and hs-CRP changed between the ALA and placebo groups, significantly but we observed no significant difference in TNF-α and IL-6 levels either within or between the groups. Conclusion: The results showed that 600 mg ALA supplementation for 12 weeks improved CIMT, FMD and hs-CRP significantly so it seems that ALA supplementation may reduce the risk of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.